<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120471</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 057</org_study_id>
    <secondary_id>10143</secondary_id>
    <nct_id>NCT00120471</nct_id>
  </id_info>
  <brief_title>Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies</brief_title>
  <official_title>A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and Their Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To prevent mother-to-child transmission (MTCT) of HIV in resource-limited countries, a simple
      yet effective treatment plan is needed. Tenofovir disoproxil fumarate (TDF) is an anti-HIV
      drug approved for use in the United States for the treatment of HIV infected adults. The
      purpose of this study is to determine the safety, tolerability, and blood levels of TDF in
      HIV infected pregnant women and their babies. The study will be conducted at sites in Malawi
      and Brazil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rates of MTCT of HIV have dramatically decreased in resource-rich countries since the
      introduction of antiretroviral (ARV) prophylaxis; increased prenatal care, HIV testing, and
      counseling; elective cesarean delivery; and avoidance of breastfeeding. In resource-limited
      countries, however, MTCT of HIV continues to be a widespread problem. In these parts of the
      world, ARV prophylaxis is too expensive and too difficult to adequately administer; mothers
      often do not receive proper prenatal care; cesarean delivery may pose risks to the mother and
      and her infant; and due to the lack of safe, affordable, and socially acceptable
      alternatives, HIV infected mothers breastfeed their infants. The purpose of this study is to
      evaluate the safety, tolerability, and pharmacokinetics (PK) of TDF in HIV infected pregnant
      women and their infants.

      Participants in this study will be enrolled through 12 months after delivery. During the last
      trimester of pregnancy, HIV infected women will be screened for eligibility. Women will be
      enrolled into the study upon presentation at the study site for delivery. Standard of care
      with ARVs for prevention of MTCT will be offered to all women and their infants both inside
      and outside of the study; however, such ARVs will not be provided by this study.

      There will be four cohorts in this study:

        -  Cohort 1 women will receive a single dose of TDF (SD TDF) during active labor. Cohort 1
           women will be hospitalized at the delivery facility through Day 3 postpartum.

        -  Cohort 2 women will not receive any TDF. Cohort 2 women will be hospitalized at the
           delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and
           on Days 3 and 5 after birth.

        -  Cohort 3 will not begin enrolling women until data safety evaluations of Cohorts 1 and 2
           are completed. Cohort 3 women will be hospitalized at the delivery facility through Day
           7 postpartum. Women in Cohort 3 will receive SD TDF during active labor, and their
           infants will receive TDF at birth and on Days 3 and 5 after birth.

        -  Cohort 4, which was added to the study based on a review of data from the other cohorts,
           will be similar to Cohort 3, except that infants will receive daily TDF for the 7 days
           after birth. Researchers believe this higher and more frequent dosing of TDF in infants
           will help them meet the target TDF concentration specified in the protocol.

      There will be seven study visits for women at study entry (Day 0), Day 2, between Days 5 and
      7, at Weeks 6 and 12, and at Months 6 and 12 postpartum. Medical history, a short physical
      exam, and blood collection will occur at all visits. In Cohorts 1, 3, and 4, blood collection
      for PK studies will occur prior to receiving TDF and seven times post-dose.

      There will be eight study visits for infants, which will occur within 24 hours of birth; on
      Day 3; between Days 5 and 7; at Weeks 6 and 12; and at Months 6, 9, and 12. Medical history,
      a physical exam, and blood collection will occur at all visits. Infants will have x-rays to
      assess bone health at Day 3 and Month 3, except in Cohort 4, which will not include x-rays of
      infants. Infants of Cohort 1 will have blood collection for PK studies at birth and four
      times after birth. Infants of Cohorts 2 and 3 will undergo blood collections for PK studies
      at birth, Day 3, and Day 5. Blood collection at these visits will occur before receiving TDF
      and 2 and 10 hours after receiving TDF. At birth, an additional collection will occur 18 to
      24 hours after receiving TDF, and on Day 5, two additional collections will occur--at 18 to
      24 hours and at 36 to 48 hours after receiving TDF. Infants of Cohort 4 will have blood
      collection for PK studies at birth and after their fourth and seventh doses of TDF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events with a severity of Grade 3 or higher attributable to receipt of TDF</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of infant serum concentrations of TDF greater than 50 ng/ml</measure>
    <time_frame>Through Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal HIV-1 RNA levels</measure>
    <time_frame>At study entry, Days 5 to 7, and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral resistance to TDF in all HIV-1 infected infants, all of the corresponding mothers (transmitters), and a subset of mothers whose infants are not infected (nontransmitters). Analysis of TDF in mothers may include testing of breastmilk samples.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV infection in infants</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDF concentration in amniotic fluid and breast milk</measure>
    <time_frame>Through Week 1</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>600-mg tablet taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>6-mg/kg oral suspension taken at birth and daily for 7 days after birth</description>
    <arm_group_label>4</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for HIV Infected Pregnant Women:

          -  HIV-1 infected

          -  Intend to deliver at the study site

          -  Willing to be contacted or visited at home

          -  Willing to be admitted to and remain in the delivery facility through Day 3 postpartum
             (Cohort 1) or Day 7 postpartum (Cohorts 2 and 3)

        Exclusion Criteria for HIV Infected Pregnant Women:

          -  Prior treatment with TDF

          -  Active opportunistic infection

          -  Serious bacterial infection

          -  Chronic malabsorption or diarrhea during the current pregnancy

          -  Clinically significant disease or condition that, in the opinion of the study
             clinician, would interfere with the study

          -  Known multiple gestation (twins, etc.) prior to study entry

          -  Participation in any other therapeutic or vaccine trial during the current pregnancy

          -  Use of certain medications

          -  Any other condition or situation that, in the opinion of the investigator, would
             interfere with the study

          -  For Cohort 4, use of atazanavir or lopinavir/ritonavir (Kaletra) within 2 weeks of
             anticipated delivery

        Exclusion Criteria for Infants Born to HIV Infected Pregnant Women:

          -  Birth weight of less than 2 kg (4.4 lbs)

          -  Severe congenital malformation or other medical condition that may affect survival
             and, in the opinion of the clinician, participation in this study

          -  Grade 2 or higher serum creatinine level or any other Grade 3 or higher toxicity

          -  Part of a multiple birth (twins, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Mirochnick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taha Taha, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regis Kreitchmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Municipal de DST/AIDS, Irmandade Santa Casa de Misericordia de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal Univ. of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao CRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Miseric√≥rdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSE-Hospital dos Servidores do Estado CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Med. JHU CRS</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Malawi</country>
  </location_countries>
  <reference>
    <citation>Abrams EJ. Prevention of mother-to-child transmission of HIV--successes, controversies and critical questions. AIDS Rev. 2004 Jul-Sep;6(3):131-43. Review.</citation>
    <PMID>15595430</PMID>
  </reference>
  <reference>
    <citation>Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med. 2005 Apr;10(2):161-75. Epub 2005 Jan 20. Review.</citation>
    <PMID>15701581</PMID>
  </reference>
  <reference>
    <citation>Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res. 2003 Oct;1(4):447-62. Review.</citation>
    <PMID>15049430</PMID>
  </reference>
  <reference>
    <citation>Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol. 2003 Feb;43(2):133-40.</citation>
    <PMID>12616665</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2005</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perinatal Transmission</keyword>
  <keyword>MTCT</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

